Radiation; Adverse Effect, Pneumonitis Clinical Trial
Official title:
Clinical, Biochemical, Dosimetric and Functional Respiratory Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer (Stages IIIa and IIIb) Treated With Chemotherapy and Radiotherapy
Lung cancer [LC] is the leading cause of cancer death worldwide. The standard treatment of
locally advanced lung cancer unresectable or marginally resectable is combination therapy
with radical or preoperative chemoradiation. The local control rates and survival with this
treatment modality have increased by more than 30%. Radiotherapy [RT] with technical molded
3D [3D-CRT, Three-Dimensional Conformal Radiation Therapy] or IMRT [intensity-modulated
radiation therapy] has allowed that the total dose of radiation has increased which leads to
a direct benefit on the results treatment.
Between 17-30% of patients are susceptible to pneumonitis due to radiation [NR]. This
complication may appear at the end of the RT or up to 6 months after the treatment. In
severe cases, mortality can reach 50%.
It's well known that in various diseases, functional abnormalities precede the clinical
manifestations. The degree of pulmonary failure secondary to RT is measured following the
standards of the Radiation Therapy Oncology Group who ranks in degrees [0 to 4].
Not precisely known factors that influence the development of NR.
Objectives:
To evaluate the effect of chemotherapy and thoracic radiotherapy on pulmonary function and
identify predictors of radiation pneumonitis in locally advanced lung cancer [stages IIIA
and IIIB].
Hypothesis:
Respiratory function tests may predict the development of radiation pneumonitis in patients
with locally advanced lung cancer who receive radical treatment with chemoradiation.
Methods Prospective cohort study with patients with locally advanced lung cancer of the Lung
Cancer Clinic of the National Cancer Institute [INCAN]. Patients will receive weekly
paclitaxel 50 mg and carboplatin AUC 2 with concomitant radiotherapy 44-63 Gy (22-33
fractions). Followup of lung function tests at baseline, during treatment with radiotherapy
and will be carried out on 4 more occasions.
;